Arch Iran Med. 2017;20(12):746-751.
PMID: 29664314
  Abstract View: 306
  PDF Download: 285

Original Article

Iran Pituitary Tumor Registry: Description of the Program and Initial Results

Mohammad Ebrahim Khamseh 1 * , Mohammad Reza Mohajeri Tehrani 2, Zohreh Mousavi 3, Mojtaba Malek 4, Mehrnaz Imani 1, Nasim Hoshangian Tehrani 1, Mohammad Ghorbani 5, Hamideh Akbari 1, Farzaneh Sarvghadi 6, Atieh Amouzegar 6, Fatemeh Esfahanian 7, Nahid Hashemi Madani 1, Zahra Emami 1

1 Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran
2 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran
3 Endocrine Research Center, Imam Reza/Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4 Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran
5 Department of Neurosurgery and Neuro-Intervention, Firoozgar hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
6 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 Department of Endocrinology, Imam Khomeini Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Corresponding Author: Mohammad Ebrahim Khamseh, MD; Endocrine Research Center, Institute of Endocrinology and Metabolism, No. 10, Firoozeh St., Valiasr Ave., Vali-asr Sq., Tehran Iran. Tel: +98-21-88945172, Fax: 98-21-88945173 Email: khamseh.m@iums.ac.ir

Abstract

Background: This study was designed to present initial results on clinical presentation, therapeutic modalities, and outcome information of patients with pituitary tumors registered in Iran Pituitary Tumor Registry (IPTR).

Methods: We collected data from a web-based electronic medical records of patients with various pituitary tumors referred to four tertiary care centers in the country. Retrospective analysis was performed on demographic, clinical, and therapeutic information of 298 patients including 51 clinically nonfunctioning adenoma (CNFA), 85 acromegaly, 135 prolactinoma, and 27 Cushing’s disease (CD).

Results: From October 2014 to July 2016, 298 people with the diagnosis of pituitary tumor were registered. Prolactinoma was the most prevalent tumor (45.3%), followed by Acromegaly (28.6%), CNFPA (17.1%), and CD (9%). Female dominance was seen among patients with prolactinoma and CD, while the majority of patients with CNFPA were male and acromegaly was equally distributed between men and women. Hypogonadal symptoms were almost always seen in all types of pituitary groups. Surgery alone was the most common therapeutic modality used in cases of acromegaly, CNFPA, and CD. However, medical therapy alone was frequently applied for cases of prolactinoma. Finally, biochemical cure was achieved in most cases of prolactinoma and CD, but only in 36.5% of acromegalics. Moreover, 80% of patients suffering from CNFPA showed no residual tumor in their imaging.

Conclusion: In conclusion, this comprehensive tumor registry enables early identification, selection of best therapeutic approaches, and evaluation of long-term treatment outcomes. Furthermore, this registry can be used to improve surveillance protocols.

Cite this article as: Khamseh ME, Mohajeri Tehrani MR,  Mousavi Z, Malek M, Imani M, Hoshangian Tehrani N, et al. Iran pituitary tumor registry: description of the program and initial results. Arch Iran Med. 2017;20(12):746–751.
First name
 
Last name
 
Email address
 
Comments
 
Security code